What are the recommended lacosamide dosing guidelines for adults with focal seizures and children aged 4–16, and how should the dose be adjusted in renal or hepatic impairment?

Lacosamide Dosing Guidelines

For adults with focal seizures, initiate lacosamide at 50 mg twice daily (100 mg/day) and titrate weekly by 100 mg/day increments to the recommended maintenance dose of 200-400 mg/day; for children aged 4-16 years, use weight-based dosing starting at approximately 2 mg/kg/day divided twice daily, titrating to 4-8 mg/kg/day (maximum 400 mg/day), with dose reductions of approximately 25% required for severe renal impairment and 25-50% for moderate-to-severe hepatic impairment.

Adult Dosing (≥17 years)

Initial and Maintenance Dosing:

• Start at 50 mg twice daily (100 mg/day total)
• Increase weekly by 100 mg/day (50 mg twice daily increments)
• Target maintenance: 200-400 mg/day divided twice daily
• Maximum dose: 400 mg/day 1

The evidence demonstrates that lacosamide is effective as both monotherapy and adjunctive therapy in adults, with sustained efficacy documented up to 8 years 1. The drug is available in oral tablets (50,100,150,200 mg) and intravenous formulations, which are bioequivalent and interchangeable at the same dosage 2, 1.

Pediatric Dosing (Ages 4-16 years)

Weight-Based Approach:

• Initial dose: ~2 mg/kg/day divided twice daily
• Maintenance dose: 4-8 mg/kg/day divided twice daily
• Maximum: 400 mg/day regardless of weight 3, 1

Age-Specific IV Dosing Recommendations (based on PBPK modeling to achieve equivalent adult exposure) 3:

• Newborns: 1.75 mg/kg
• Toddlers (1-3 years): 2.5 mg/kg
• Preschool/School age (4-11 years): 2.2 mg/kg
• Adolescents (12-16 years): 2 mg/kg

Simplified Body Weight Band Dosing (validated alternative to mg/kg dosing) 4:

• Patients ≥10 kg: Fixed 100 mg dose achieves equivalent exposure to weight-adjusted dosing
• This approach maintains >78% target attainment and simplifies administration

The efficacy in children aged 4-16 years has been extrapolated from adult data with preliminary 16-week studies confirming effectiveness and tolerability in this age group 1.

Renal Impairment Adjustments

Dose reductions are mandatory for severe renal dysfunction 5:

• Mild impairment (CrCl 50-80 mL/min): No adjustment needed (only ~20% decrease in clearance)
• Moderate impairment (CrCl 30-50 mL/min): Reduce dose to ~75% of normal adult dose
• Severe impairment (CrCl <30 mL/min): Reduce dose to ~63% of normal adult dose
• End-stage renal disease (ESRD): Reduce dose to ~76% of normal adult dose

Hemodialysis Considerations: Approximately 50% of lacosamide is removed during a 4-hour hemodialysis session 5. Supplemental dosing after hemodialysis is recommended to maintain therapeutic levels. The terminal half-life increases and systemic exposure rises with worsening renal function, while renal clearance (normally ~30% of total clearance) decreases proportionally 5.

Hepatic Impairment Adjustments

Dose reductions based on Child-Pugh classification 3:

• Child-Pugh A (mild): Reduce to ~89% of normal adult dose
• Child-Pugh B (moderate): Reduce to ~72% of normal adult dose
• Child-Pugh C (severe): Reduce to ~36% of normal adult dose

These substantial reductions in severe hepatic dysfunction reflect the 50% decrease in apparent clearance observed in patients with severe liver disease 3. Even though lacosamide undergoes predominantly renal elimination, hepatic metabolism still accounts for approximately 70% of total clearance, making dose adjustment critical in liver disease.

Special Considerations

Elevated Uric Acid: In pediatric patients with uric acid levels >400 μmol/L, reduce the dose by approximately 50% compared to patients with normal uric acid (100 μmol/L) 6. This represents a clinically significant pharmacokinetic interaction affecting clearance.

CYP2C19 Genotyping: While CYP2C19 polymorphisms showed no clinically significant impact in some studies 6, genotype-guided dosing models demonstrated superior predictive performance and may enhance precision in select patients 4.

Drug Interactions: Concomitant non-hepatic enzyme-inducing antiepileptic drugs (such as valproic acid, levetiracetam) increase lacosamide serum concentrations and concentration-to-dose ratios 7. However, common AEDs including valproic acid, levetiracetam, oxcarbazepine, lamotrigine, and perampanel do not require routine dose adjustments 6.

Cardiac Monitoring: Lacosamide is associated with cardiac rhythm and conduction disturbances 8. ECG monitoring is required in patients with pre-existing cardiac disease, particularly those with conduction abnormalities. Avoid first-line use of cardiotoxic antiseizure medications like phenytoin when lacosamide is prescribed 9.

Critical Safety Warnings

• DRESS Syndrome Risk: Lacosamide can cause Drug Rash with Eosinophilia and Systemic Symptoms; use cautiously in patients with allergy history 8
• Psychiatric Effects: Monitor intensively for depression and psychosis, especially in patients with psychiatric history 8
• Seizure Prophylaxis: For patients with CNS disease or seizure history receiving other therapies (e.g., CAR T-cell therapy), lacosamide should generally be avoided as first-line prophylaxis; levetiracetam is preferred (10 mg/kg up to 500 mg every 12 hours) 9

The dosing strategy should account for body surface area in children, renal function via creatinine clearance, hepatic function via Child-Pugh score, and potential drug interactions with non-enzyme-inducing AEDs to optimize therapeutic outcomes while minimizing adverse effects 3, 5, 6, 7.